FY2023 EPS Estimates for Avantor, Inc. (NYSE:AVTR) Lowered by Analyst

Avantor, Inc. (NYSE:AVTR) – Analysts at William Blair cut their FY2023 earnings estimates for shares of Avantor in a research report issued on Monday, October 30th. William Blair analyst M. Larew now anticipates that the company will post earnings per share of $1.04 for the year, down from their prior estimate of $1.06. William Blair has a “Market Perform” rating on the stock. The consensus estimate for Avantor’s current full-year earnings is $1.06 per share. William Blair also issued estimates for Avantor’s Q4 2023 earnings at $0.22 EPS, Q1 2024 earnings at $0.25 EPS, Q2 2024 earnings at $0.27 EPS, Q3 2024 earnings at $0.30 EPS, Q4 2024 earnings at $0.32 EPS and FY2024 earnings at $1.14 EPS.

Several other equities research analysts have also recently issued reports on AVTR. Robert W. Baird lowered their target price on shares of Avantor from $24.00 to $22.00 and set an “outperform” rating on the stock in a research note on Monday, July 31st. Raymond James lowered their target price on shares of Avantor from $25.00 to $22.50 and set an “outperform” rating on the stock in a research note on Monday. Royal Bank of Canada lifted their target price on shares of Avantor from $27.00 to $28.00 and gave the stock an “outperform” rating in a research note on Monday, July 31st. Bank of America lowered their target price on shares of Avantor from $27.00 to $24.00 and set a “buy” rating on the stock in a research note on Sunday, July 30th. Finally, Morgan Stanley lowered their target price on shares of Avantor from $24.00 to $22.00 and set an “overweight” rating on the stock in a research note on Monday. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $24.88.

Avantor Price Performance

Avantor stock opened at $17.43 on Tuesday. Avantor has a 1 year low of $16.63 and a 1 year high of $25.25. The company has a debt-to-equity ratio of 1.11, a quick ratio of 1.04 and a current ratio of 1.61. The company’s fifty day moving average price is $20.95 and its 200 day moving average price is $20.67. The stock has a market capitalization of $11.78 billion, a P/E ratio of 32.28, a P/E/G ratio of 1.02 and a beta of 1.28.

Avantor (NYSE:AVTR) last released its quarterly earnings results on Friday, October 27th. The company reported $0.25 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.25. Avantor had a net margin of 5.18% and a return on equity of 15.45%. The firm had revenue of $1.72 billion for the quarter, compared to analysts’ expectations of $1.70 billion. During the same quarter last year, the company earned $0.34 EPS. The firm’s revenue for the quarter was down 7.3% compared to the same quarter last year.

Institutional Trading of Avantor

A number of institutional investors and hedge funds have recently bought and sold shares of the business. T. Rowe Price Investment Management Inc. increased its stake in Avantor by 32.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 76,325,881 shares of the company’s stock worth $1,609,713,000 after purchasing an additional 18,711,696 shares during the period. Vanguard Group Inc. increased its stake in Avantor by 0.9% during the first quarter. Vanguard Group Inc. now owns 50,759,035 shares of the company’s stock worth $1,716,671,000 after purchasing an additional 439,147 shares during the period. BlackRock Inc. increased its stake in Avantor by 4.6% during the second quarter. BlackRock Inc. now owns 44,660,832 shares of the company’s stock worth $917,333,000 after purchasing an additional 1,984,205 shares during the period. Boston Partners grew its position in shares of Avantor by 41.1% during the second quarter. Boston Partners now owns 23,128,075 shares of the company’s stock worth $475,175,000 after buying an additional 6,736,666 shares in the last quarter. Finally, Barrow Hanley Mewhinney & Strauss LLC acquired a new position in shares of Avantor during the first quarter worth about $342,202,000. 89.04% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Avantor

In related news, CAO Steven W. Eck sold 7,577 shares of the business’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $20.64, for a total value of $156,389.28. Following the sale, the chief accounting officer now directly owns 28,187 shares in the company, valued at approximately $581,779.68. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Avantor news, EVP Frederic Vanderhaegen sold 25,000 shares of the business’s stock in a transaction dated Friday, August 25th. The shares were sold at an average price of $21.47, for a total transaction of $536,750.00. Following the sale, the executive vice president now directly owns 160,735 shares in the company, valued at $3,450,980.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Steven W. Eck sold 7,577 shares of the business’s stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $20.64, for a total transaction of $156,389.28. Following the sale, the chief accounting officer now owns 28,187 shares in the company, valued at $581,779.68. The disclosure for this sale can be found here. 1.50% of the stock is owned by insiders.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.